Malignant Rectal Neoplasm — Trials

Malignant Rectal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,549 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 386
Recruiting: 215
Ph III recruiting: 36
Growth YoY: +9.8%
Industry share: 5%
Top sponsor: Fudan University
Termination share: 28%
Trials / 1,000 deaths: 29.9 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (153)

clinicaltrialsPublishedShowing 1–36 of 36 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05610163	Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS)	active not recruiting	Phase 2 / Phase 3	760	Alliance for Clinical Trials in OncologyOTHER	2	Sep 25, 2026	clinicaltrials
NCT05585814	CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer(COBP)	active not recruiting	Phase 2